SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced a $45 million gift to the Intuitive Foundation that will be used to support the Foundation’s mission of reducing the global burden of disease and suffering through philanthropy, research, and education aimed at better outcomes for patients everywhere. This latest donation brings the contributions made by Intuitive to the Foundation to more than $170 million since it was founded in 2018.
“We are pleased to support the important work that the Intuitive Foundation undertakes in providing health and medical fellowships and grants worldwide, and programs that support STEM and other research endeavors,” said Intuitive CEO Gary Guthart.
The Intuitive Foundation promotes health and advances education by making grants for medical research, STEM educational programs, training, surgical fellowships, healthcare training programs and facilities, and other similar purposes. Since its inception, the Foundation has committed more than $65 million to causes in support of its mission.
In 2024 alone, the Foundation matched the generosity of Intuitive employees through its donation-matching program, providing more than $7 million to support more than 2,000 causes.
“Amplifying the voice of Intuitive employees and the causes that are meaningful to them is a key pillar of the Intuitive Foundation’s philanthropic giving,” said Intuitive Foundation President Catherine Mohr, MD. “Additionally, in 2024, we were able to provide research grants and surgical fellowships totalling more than $6 million, and we were able to contribute $3 million to support the Surgical Education Learners Forum, which develops training modules for clinicians in low-resource settings.”
Key programs of the Foundation include:
About Intuitive Surgical, Inc.
Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
For more information, please visit the company’s website at www.intuitive.com.
About Intuitive Foundation
The Intuitive Foundation is dedicated to reducing the global burden of disease and suffering through philanthropy, research and education aimed at better outcomes for patients everywhere. The Foundation was created in 2018 to promote health and advance education by making grants to section 501(c)(3) organizations and foreign charities for medical and technology research; science, technology, engineering, and math-related educational programs, training, and fellowships; healthcare training programs and facilities; direct disaster relief; and for other similar purposes.
For more information, please visit the Foundation’s website at www.intuitive-foundation.org
PRESS CONTACT
U.S.: Peper Long, Intuitive
202-446-7748 – mobile
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$490.13 |
Daily Change: | -3.47 -0.70 |
Daily Volume: | 1,429,131 |
Market Cap: | US$174.570B |
March 03, 2025 January 23, 2025 January 21, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load